BRKR Stock Recent News

At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.

CHICAGO--(BUSINESS WIRE)---- $BRKR #BRKR--At the Neuroscience 2024 conference, Bruker Corporation (Nasdaq: BRKR) today announced the release of the OptoVolt™ module to further expand the advanced neuroscience research capabilities on Bruker's Ultima multiphoton microscope platform. OptoVolt accelerates imaging speeds to beyond 1000 frames per second for the capture of millisecond dynamics of cell-to-cell neural communication. With the emergence of fluorescent voltage indicators, researchers are excited to meas.

Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. Dynamic Biosensors (DBS) de.

Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.

Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Diagnostic Devices Market (2024 Edition): Analysis by Type (Imaging Devices, Microscopes, Immunoassays, Molecular Diagnostics, Others), Application, End-user and Region: Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. This report provides a complete analysis of the Global Dermatology Diagnostic Devices industry for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The Global Dermatology Diagnostic Devices market showcased growth at a CAGR of 10.29% during 2020-2023. The market was valued at USD 7.57 billion in 2023, and is expected to reach USD 17.65 billion in 2030.

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Under a strategic partnership with Alamar Biosciences, Biognosys is a provider of choice of NULISA multiplex assay services for biopharma research The NULISAseq™ CNS Disease and Inflammation panels are now available for customers as a contract research service from Biognosys' high-end proteomics facility in Europe By offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomics ZURICH and NEWTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: 2024 Wells Fargo Healthcare Conference in Boston, MA Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time Morgan Stanley 22nd Annual Global Healthcare Conference in New York City Friday, September 6, 2024, at 10:00 a.m. Eastern Time Live audiovisual webcasts of the presentation.